Dr. Johannes B. Woehrstein is Co-Founder and CEO at mbiomics, a pioneering techbio company developing scalable microbiome-based therapeutics for severe and chronic diseases.

Johannes is a physicist and serial entrepreneur who conducted research at the Wyss Institute at Harvard University and led a research group as Principal Investigator at LMU Munich, focusing on single-cell genomics and super-resolution microscopy.

Johannes invented multiple technologies that led to the launch of several biotech companies, including Ultivue and DEOXY, and published groundbreaking research in Science Advances with over 2,700 citations. He holds a PhD in Physics from Ludwig Maximilian University Munich.

mbiomics raised 30 million EUR in Series A funding led by MIG Capital, Bayern Kapital, and HTGF, and is advancing lead candidate MBX-116 for clinical evaluation in advanced melanoma with a Phase 1B study planned for 2027.

The company built a proprietary AI/ML-driven platform combining precision analytics, large consortium co-cultivation, and screening capabilities to design complex microbial consortia with over 100 bacterial strains, addressing a market projected to reach 10 to 15 billion USD by 2030.